- SEK12.68bn
- SEK12.35bn
- SEK1.86bn
Annual income statement for Biotage AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1,101 | 1,092 | 1,232 | 1,566 | 1,862 |
| Cost of Revenue | |||||
| Gross Profit | 685 | 667 | 755 | 948 | 1,149 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 893 | 886 | 961 | 1,239 | 1,548 |
| Operating Profit | 208 | 206 | 271 | 327 | 314 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | 212 | 223 | 269 | 348 | 303 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | 187 | 175 | 205 | 268 | 246 |
| Net Income Before Extraordinary Items | |||||
| Net Income | 187 | 175 | 205 | 268 | 246 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | 187 | 175 | 205 | 268 | 246 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | 2.9 | 2.69 | 3.18 | 4.47 | 4.41 |
| Dividends per Share |